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Sudafed PE Nasal Decongestant 
Lead author: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor 
 
What It Is 
Sudafed PE Nasal Decongestant is a new OTC 
version of Sudafed Nasal Decongestant.  It 
contains 10 mg of phenylephrine instead of 30 mg 
of pseudoephedrine as the only active ingredient.  
 
How It Works 
Phenylephrine is a sympathomimetic amine 
that primarily exhibits direct alpha-adrenergic 
receptor stimulation.  Because of its potent 
vasoconstrictor effects on nasal vasculature, it 
causes shrinkage of nasal mucosa, thereby acting 
as a decongestant.1,2 
 
Indications 
The indications for Sudafed PE are the same as 
the indications for Sudafed.  These include 
temporary relief of nasal congestion due to the 
common cold, hay fever, or other upper 
respiratory allergies, and nasal congestion 
associated with sinusitis.  It is also indicated for 
temporary relief of sinus congestion and pressure.3 
 
How Supplied 
Sudafed PE is supplied in a tablet dosage form 
in boxes of 18, 36, and 72 tablets.  The AWP for a 
box of 18 tablets is $4.29 as compared with 
Sudafed in a box of 24 tablets at $4.29.4 
 
Dosage 
The dosage for adults and children 12 years of 
age and over is one tablet taken every 4 hours 
with not more than six doses in a 24 hour period.  
For children under 12 years, the advice of a 
physician must be sought.3 
 
Adverse Effects 
As described in the product information, 
nervousness, dizziness, and insomnia may occur 
and warrant discontinuation of Sudafed PE.3  
Other systemic effects of phenylephrine include 
anxiety, weakness, tremor, headache, pallor or 
blanching of the skin, respiratory distress, 




Nonselective beta-blockers, methyldopa, 
reserpine, guanethidine, and tricyclic 
antidepressants may increase hypertensive effects 
of phenylephrine.  MAO inhibitors potentiate 
cardiac and pressor effects of phenylephrine.  
Concurrent use of any of these agents should be 
avoided.  Coadministration of phenylephrine with 
cocaine may cause malignant arrhythmias, and 
use with ephedra or yohimbe can result in 
excessive CNS stimulation.1,5 
 
Contraindications 
Sudafed PE is contraindicated in 
hypersensitivity to phenylephrine or any 
component of the formulation, as well as other 
sympathomimetic drugs; in severe hypertension, 
ventricular tachycardia, and severe coronary 




Sudafed PE should be used with caution and a 
physician should be consulted prior to use in 
patients with hyperthyroidism, diabetes mellitus, 
hypertension, ischemic heart disease, and urinary 
retention.  Patients experiencing nervousness, 
dizziness, or insomnia during current use should 
discontinue treatment.  Treatment with Sudafed 
PE should cease whenever symptoms persist for 
seven days or are accompanied by fever.1,3 
 
Use In Pregnancy 
Phenylephrine is a Pregnancy Category C 
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Manufacturer 
Pfizer 
235 East 42nd Street 





Pfizer’s decision to market Sudafed PE results 
from the current and ongoing problem of 
methamphetamine manufacturing using 
pseudoephedrine as a chemical precursor.  Pfizer 
will continue to market Sudafed with its 
pseudoephedrine content.  This action enables 
Pfizer to maintain an overt “front shelf” presence 
of its Sudafed PE product wherever over-the-
counter products are sold.  At the same time, 
Pfizer retains the broad availability of Sudafed 
even in states requiring pseudoephedrine product 
storage behind-the-counter.  Sudafed PE is 
currently available at the wholesale distribution 
level.   
The Meth Watch program sponsored by the 
Consumer Healthcare Products Association 
(CHPA) is active in several states.  Its goal is to 
promote cooperation between retailers and law 
enforcement to prevent diversion of legitimate 
products for purposes of methamphetamine 
production.  The program encourages restricted 
access and observation of precursor ingredient 
purchase such as over-the-counter cold, cough, or 
allergy medicines containing pseudoephedrine or 
ephedrine as well as household supply items such 
as rubbing alcohol, lye, iodine, and others used to 
manufacture methamphetamine.  Please see 
Detail-Document #200809, Methamphetamine 
and the Meth Watch Program for more 
information on this topic. 
The substitution of phenylephrine for 
pseudoephedrine will eliminate the chemical 
conversion possibility of methamphetamine 
production from Sudafed PE.   
The nasal decongestant efficacy of oral 
phenylephrine vs. pseudoephedrine may not be 
the same.  Pharmacologically, phenylephedrine is 
a direct alpha-adrenergic agonist in therapeutic 
doses whereas pseudoephedrine has both alpha-
and, to a lesser degree, beta-adrenergic activity.  
Pseudoephedrine also exerts an indirect effect 
causing release of norepinephrine from storage 
sites.1,2,5  Phenylephrine has a shorter elimination 
half-life of 2.5 hours compared to 
pseudoephedrine with a nine to 16 hour half-life.5  
Furthermore, it is believed that orally 
administered phenylephrine undergoes first-pass 
hepatic metabolism, whereas pseudoephedrine 
does not.6  In a nasal airway resistance study 
conducted by Bickerman, the single-dose efficacy 
of pseudoephedrine 60 mg, phenylpropanolamine 
40 mg, phenylephrine 10 mg, and placebo were 
compared.  Pseudoephedrine and 
phenylpropanolamine decreased nasal airway 
resistance whereas phenylephrine was no more 
effective than placebo.7  The FDA has classified 
phenylephrine in an oral dose of 10 mg as 
effective and safe.8 
With phenylephrine’s first-pass metabolism 
and its short elimination half-life, yet its 
unopposed pure alpha-agonist effects, it is 
unknown if it presents a more favorable safety 
profile than pseudoephedrine.5,6  The lowest dose 
that may elevate blood pressure in normotensive 
patients, as identified in a single study, was 45 mg 
or higher.9  No clear evidence exists that either 
drug is safer in patients with hypertension.  
Randomized controlled trials or meta-analyses 
directly comparing phenylephrine with 
pseudoephedrine are not available.  Both drugs 
can prolong QT intervals.10 
As identified in the product label, Sudafed PE 
should be used with caution and a physician 
should be consulted prior to use in patients with 
hyperthyroidism, diabetes mellitus, hypertension, 
ischemic heart disease, and urinary retention.  
Patients experiencing nervousness, dizziness, or 
insomnia during current use should discontinue 
treatment.  Treatment with Sudafed PE should 
cease whenever symptoms persist for seven days 
or are accompanied by fever.1,3 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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